Truist raised the firm's price target on Madrigal Pharmaceuticals to $709 from $640 and keeps a Buy rating on the shares. The firm's survey work reinforces its belief in the sizable MASH patient numbers eligible for treatment that will translate to significant Rezdiffra revenues for Madrigal, the analyst tells investors in a research note, adding that Truist is increasing the US peak MASH patients treated with Rezdiffra estimates to 193K from 158K prior.
